Proscia
- Industry
- Healthcare Software
- Founded Year
- 2014
- Headquarters
- Philadelphia, Pennsylvania, United States
- Employee Count
- 111
Key People
- David West - Co-Founder & CEO
- Coleman Stavish - Co-Founder & CTO
- Nathan Buchbinder - Co-Founder
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced entrepreneurs with a strong background in medical technology.
Proscia's leadership includes individuals with proven track records in MedTech entrepreneurship, enhancing the company's credibility and potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: Proscia addresses a critical need in digital pathology, enhancing diagnostic accuracy and efficiency.
With the global digital pathology market projected to grow at a CAGR of 8.1%, Proscia's offerings are well-aligned with industry needs.
- Competition
-
Aspect: Somewhat crowded
Summary: The digital pathology market has several established players, but Proscia maintains a competitive edge.
Competitors include companies like Leica Biosystems and Paige AI, but Proscia's AI-driven solutions offer unique value propositions.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing AI-driven pathology solutions presents moderate technical challenges.
Integrating AI into pathology requires overcoming challenges related to data quality and algorithm accuracy, but these are within Proscia's capabilities.
- Patent
-
Aspect: Strong
Summary: Proscia holds strong patents that protect its innovative technologies.
Proscia's patents cover key aspects of its digital pathology solutions, safeguarding its market position.
- Financing
-
Aspect: Well-funded
Summary: Proscia has secured substantial funding, indicating strong financial health.
With total funding of $129M, including a recent $50M round led by Insight Partners, Proscia is well-positioned for future expansion.
- Regulatory
-
Aspect: 510k/PMA
Summary: Proscia has achieved necessary regulatory clearances for its products.
Proscia's Concentriq platform has received FDA 510(k) clearance and CE-IVDR certification, ensuring adherence to industry regulations.
Opportunity Rollup
- Odds of Success
- 3.6
- Peak Market Share
- 4.6
- Segment CAGR
- 8.1%
- Market Segment
- Digital Pathology
- Market Sub Segment
- AI-Driven Diagnostic Solutions
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.23 |
| 2 | 0.69 |
| 3 | 1.61 |
| 4 | 3.22 |
| 5 | 4.60 |
Key Takeaway
Proscia is well-positioned in the growing digital pathology market, leveraging AI to meet increasing demand for precision medicine solutions.